Selected Slide Presentations
Click on the links below to view presentations.

State of the Art Lecture
Successes and failures in HIV drug development: Are there lessons for HCV? (Robert Schooley)

Implications of Viral Drug Resistance
The clinical interpretation of HIV drug resistance (Anna Maria Geretti)

Re-evaluating the cost-effectiveness of HAART based on its effect on secondary prevention of HIV infection (Julio Montaner)

Activity of an HIV-1 maturation inhibitor in vitro requires assembled Gag (Michael Sakalian)

Preventive Technologies: Microbicides and Vaccines
Vaccine development overview (Tomás Hanke)

Drug Discovery and Development I: Chemistry and Pre-Clinical Development
New drugs in development and their potential clinical use (David Cooper)

Salvage and Alternative Therapies
Racivir as second line therapy (Pedro Cahn)

The role of NNRTIs in treatment experienced patients - an update on TMC125 (Brian Woodfall)

Drug Discovery and Development II: Viral Targets
Clinical development of an HIV-1 integrase inhibitor GS-9137 (Jeff Enejosa)

Validation of the translocational equilibrium of HIV-1 RT as a specific target (Matthias Götte)

Safety and Effectiveness of Antiretroviral Agents
Complications of antiretroviral therapy: Current issues (Christine Katlama)

Evaluating cardiac toxicity of antiretroviral agents (Judith Currier)

The immune system and complications of HIV therapy (Richard Pollard)

HIV Reservoirs and Immunotherapy
VS411: An immunomodulating drug combination to inhibit both HIV and immune activation (Franco Lori)

HIV/Hepatitis and Other Co-Infections
New therapies for HCV and HBV (Bruce Polsky)

Clinical management of co-infected patients (Robert Murphy)

Late Breaker Abstracts
Vicriviroc as a component of HAART in treatment-naive individuals: Final analysis of Study 3802 (Lisa Dunkle)

Similar changes in metabolic parameters of darunavir (TMC114) and atazanavir, each coadministered with low-dose ritonavir in healthy volunteers (Frank Tomaka)